Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Sun Pharma hits all-time high after unit Taro's results
Yahoo/Reuters
Monday, November 10, 2014 - 8:07am
tags:
Sun Pharma, Taro, earnings
Dendreon Files for Chapter 11 Bankruptcy Protection
Bloomberg
Monday, November 10, 2014 - 7:58am
tags:
Dendreon, bankruptcy
Merck’s Four-Week Hepatitis C Regimen Fails to Top Gilead
Bloomberg
Monday, November 10, 2014 - 7:57am
tags:
hepatitis C, Merck, Gilead Sciences, grazoprevir, elbasvir, Sovaldi
Intercept Pharmaceuticals Below $180: Mega Millions Vanish
Forbes
Sunday, November 9, 2014 - 10:29am
tags:
Intercept Pharmaceuticals
After hep C cure, companies target next big liver disease market
Yahoo/Reuters
Sunday, November 9, 2014 - 9:46am
tags:
hepatitis B, hepatitis, nonalcoholic steatohepatitis, Gilead, Galmed Pharmaceuticals, Raptor Pharmaceuticals, Conatus Pharmaceuticals
US FDA grants fast tract status to MorphoSys's MOR208 programme to treat DLBCL
PharmaBiz
Saturday, November 8, 2014 - 11:39am
tags:
diffuse large B-cell lymphoma, lymphoma, MorphoSys, MOR208
ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients
Yahoo/BusinessWire
Saturday, November 8, 2014 - 11:35am
tags:
daclatasvir, sofosbuvir, hepatitis C, hepatitis, Bristol-Myers Squibb
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)
Yahoo/Globe NewsWire
Saturday, November 8, 2014 - 10:39am
tags:
Achillion, ACH-3102, ACH-3422, HCV, hepatitis C
Neuralstem Among Our 'Best for 2015' Biotech Names
Yahoo/Zacks
Saturday, November 8, 2014 - 10:35am
tags:
Neuralstem
Biotech stocks to watch ahead of liver disease conference
CNBC
Friday, November 7, 2014 - 3:54pm
tags:
liver disease, Gilead Sciences, Intercept Pharma, Genfit, Merck, Achillion, AbbVie, NASH, hepatitis B, hepatitis C
Dealpolitik: Controversial Takeover Alliances Unlikely After Court Ruling
WSJ Online
Friday, November 7, 2014 - 3:49pm
tags:
Allergan, Valeant Pharmaceuticals, M&A
Ackman to Allergan board: Valeant can pay more for company
Yahoo/Reuters
Friday, November 7, 2014 - 12:30pm
tags:
Bill Ackman, M&A, Allergan, Valeant Pharmaceuticals
Medivation Hits High After Q3 Earnings Beat
Investors.com
Friday, November 7, 2014 - 12:29pm
tags:
Medivation, earnings
Gilead Sciences: Another Big Jump in Hep-C Prescriptions
Barron's
Friday, November 7, 2014 - 10:30am
tags:
Gilead Sciences, hepatitis C, Sovaldi, Harvoni
Aeterna Zentaris bottoms out after a stinging FDA rejection
Fierce Biotech
Friday, November 7, 2014 - 10:15am
tags:
Aeterna Zentaris, FDA, macimorelin
Why AbbVie Inc.'s Game-Changing New Drug Could Be a Serious Threat to Gilead Sciences Inc.
Motley Fool
Friday, November 7, 2014 - 10:11am
tags:
AbbVie, Gilead Sciences, Enanta, Harvoni, hepatitis C
Allergan Should Run an Auction, Hostile Hedge Fund Says
Bloomberg
Friday, November 7, 2014 - 10:05am
tags:
Allergan, M&A
DOJ interested in Impax Labs paper trail
Seeking Alpha
Friday, November 7, 2014 - 9:04am
tags:
Impax Labs, DOJ
Isis beats 3Q profit forecasts
Yahoo/AP
Friday, November 7, 2014 - 8:52am
tags:
Isis Pharmaceuticals, earnings
[video] Treat Sickness as Biodefense Threat: GlaxoSmithKline CEO
Bloomberg
Friday, November 7, 2014 - 8:49am
tags:
GSK, biodefense drugs, Andrew Witty

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.